AI-generated analysis. Always verify with the original filing.
Atossa Therapeutics issued a press release on March 25, 2026, announcing fourth quarter and full year 2025 financial results, with total operating expenses of $37.1 million for the year ended December 31, 2025, up $9.5 million from $27.6 million in 2024, primarily due to increased R&D on (Z)-endoxifen trials. The company highlighted FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in DMD and management team additions.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On March 25, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the fourth quart
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 25, 2026 104 Cover page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Total Operating Expenses | $37.10 | |
| Research and Development Expense | $21.19 | |
| General and Administrative Expense | $15.96 | |
| Interest Income | $2.40 |